Matteo Falzoi

Matteo Falzoi

Auto-generated profile, based on publicly available information

Matteo Falzoi

Consorzio ELPRO, Edificio 5, Loc. Piscinamanna, 09010 Pula, CA, Italy; Dipartimento di Scienze della Vita e dell'Ambiente, Lab. Genetica, Università di Cagliari, Via T. Fiorelli 1, 09126 Cagliari, CA, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GMGabriele Murineddu
Gabriele Murineddu
PLPaolo Lazzari
Paolo Lazzari
SRStefania Ruiu
Stefania Ruiu
ASAngela Sanna
Angela Sanna
GLGiovanni Loriga
Giovanni Loriga
GPGérard A. Pinna
Gérard A. Pinna

1 April 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IMIlaria Manca
Ilaria Manca
Andrea MastinuAndrea Mastinu
Andrea Mastinu
FOFrancesca Olimpieri
Francesca Olimpieri
MFMatteo Falzoi
Matteo Falzoi
MSMonica Sani
Monica Sani
PLPaolo Lazzari
Paolo Lazzari

1 April 2007 in Brain Research
Verified
Journal Article
Closed access
MCMaria Antonietta Casu
Maria Antonietta Casu
ASAngela Sanna
Angela Sanna
GSGabriele Pinna Spada
Gabriele Pinna Spada
MFMatteo Falzoi
Matteo Falzoi
RMRaymond Mongeau
Raymond Mongeau
LPLuca Pani
Luca Pani

1 July 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GPGiovanni Pinna
Giovanni Pinna
GLGiovanni Loriga
Giovanni Loriga
PLPaolo Lazzari
Paolo Lazzari
SRStefania Ruiu
Stefania Ruiu
MFMatteo Falzoi
Matteo Falzoi
GPGerard A. Pinna
Gerard A. Pinna

29 March 2010 in Pharmacogenomics
Verified
Journal Article
Closed access
MFMatteo Falzoi
Matteo Falzoi
AMAlessandra Mossa
Alessandra Mossa
ECElena Congeddu
Elena Congeddu
LSLuisella Saba
Luisella Saba
LPLuca Pani
Luca Pani
Pharmacogenetics is the study of genetic variations that cause alterations in drug level, drug response and adverse drug reactions. SNPs found in CYP450 genes have the greatest genetic influences on interindividual variability in drug bioavailability. The polymorphic nature of these genes may modulate several enzyme levels that affect individual responses to pharmacological treatment. Among them, CYP3A4, CYP3A5, CYP2C9 and CYP2C19 isoforms of CYP450 enzymes are involved in the metabolism of many commonly prescribed drugs. In this study, we would like to develop a CYP450 genotyping platform that could lead a complete definition of a patient's metabolic genotype in order to improve the clinical outcome of some drug treatments. We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Sequenom) to develop a SNP genotyping method. This MALDI-TOF-based multiplexing system allows the simultaneous and efficient genotyping of a set of CYP450 gene polymorphisms. The multiple CYP450 gene testing achieved with this application can be used to develop diagnostic tests to predict drug responses and clinical outcomes.

5 November 2013 in ISRN Genetics
Verified
Journal Article
Open access
PDF file
MFMatteo Falzoi
Matteo Falzoi
LPLuigi Pira
Luigi Pira
PLPaolo Lazzari
Paolo Lazzari
LPLuca Pani
Luca Pani
The CYP2D6 enzyme is involved in the metabolism of many commonly prescribed drugs. The presence of polymorphisms in the CYP2D6 gene may modulate the enzyme level and activity affecting individual responses, to pharmacological treatment in drug level, response and adverse reactions. Aims. This study aimed to analyze the determination of allele frequencies in Sardinians and the comparison to frequencies found in the Caucasian Population. Methods and Materials. We used a Long PCR strategy coupled to direct genomic DNA sequencing analysis. An amplification allele-specific was carried out to infer the correct allelic phase. The TaqMan Gene Copy Number Assay (Applied Biosystems) was used to verify the presence of gene deletions/multiplications. Results and Conclusions. Our results indicated that CYP2D6 allele frequencies in Sardinians differed from those previously detected in the Caucasian Population. Moreover, three new SNPs and four novel haplotypes were identified.